Home
>
Stocks
>
Sun Pharma Advanced Research Company Limited

Sun Pharma Advanced Research Company Limited

SPARC

190.10
0.71
(
0.37
%)
1D

Performance

Today's High
192.95
Today's Low
188.15
52W High
52.0
52W Low
52.0
Open Price
52.0
Prev. Close
52.10
Volume
52.0
Value
522 Cr.

Fundamentals

Market Cap
₹39,910Cr
P/E Ratio(TTM)
NA
P/B ratio
2.21
Industry P/E
-2.47
Debt to Equity
0.03
ROE
-10.01%
EPS(TTM)
-1.13
EPS(TTM)
-1.13
Book Value
25.84
Face Value
1

About

Sun Pharma Advanced Research Company Limited

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, dermatology, and Immunology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet to develop an S1P receptor 1 agonist for autoimmune disorders. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited.

ITC
2
HDFC Bank
2
Tata Consultancy Services
1
Top Gainers
Tata motors
1.28
SAIL
2.00
Gail
2.80
Top Losers
Britannia
-2
Adani
2